Based on the endogenous NAIP functions, we previously developed NAIP-based drug screening (NAIP-ELISA) system [9], and demonstrated that the NAIP upregulating compounds exerted not only selective anti-oxidative stress activity in vitro[9], [10] but also in vivo efficacy in a transgenic ALS mouse model carrying the H46R mutation in SOD1 gene [ALS(SOD1H46R)] [10], [11]. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.